Key facts
- It has raised $411.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($411.0M) in Jan 2025.
- Notable investors include RA Capital Management, OrbiMed, General Atlantic, Forbion, Logos Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Verdiva Bio
Funding rounds
1 roundsAbout Verdiva Bio
Developer of next-generation therapies designed to help people living with obesity, cardiometabolic disorders, and related complications. The company accelerates the development of differentiated medicines that address unmet medical needs in gut-brain biology and include multiple amylin molecules, enabling users to access the potential for enhanced efficacy, improved tolerability, and healthier weight loss.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Guildford, United Kingdom
- Founded
- 2024
- Employees
- 41
- Website
- verdivabio.com/
- Ownership
- Privately Held (backing)
Verdiva Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verdiva Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verdiva Bio in its N-PORT filings yet. We sweep new filings monthly.